For instance, AURKA inhibitors, effective in RB1 and PTEN mutant tumours [149, 150, 183], could be trialed in tumours with mutations in less-studied tumour suppressors, such as FBXW7 and NSD1, for which we found AURKA to be a key gene in classification. The gene discussed is PTEN; the disease is neoplasm.